Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

NCT00019656 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: perifosine

Sponsor

National Cancer Institute (NCI)